Drug Price Trends for EMGALITY

Average Pharmacy Cost for EMGALITY

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
EMGALITY 120 MG/ML SYRINGE	00002-2377-01	680.58752	ML	2024-12-18
EMGALITY 300 MG DOSE (100 MG/ML X 3 SYRINGES)	00002-3115-09	567.91637	ML	2024-12-18
EMGALITY 120 MG/ML PEN	00002-1436-01	680.70964	ML	2024-12-18
EMGALITY 120 MG/ML PEN	00002-1436-11	680.70964	ML	2024-12-18

EMGALITY Market Analysis and Financial Projection

Market Analysis and Price Projections for Emgality

Market Overview of Migraine Drugs

The migraine drugs market is experiencing significant growth, driven by advancements in treatment processes and the increasing prevalence of migraines. As of 2023, the migraine drugs market size was valued at US$ 4.2 billion and is projected to reach US$ 6.3 billion by 2032, with a Compound Annual Growth Rate (CAGR) of 4.3% during the forecast period[1].

Role of Emgality in the Market

Emgality, developed by Eli Lilly, is a key player in this market. It is a calcitonin gene-related peptide (CGRP) inhibitor, approved for the preventive treatment of migraine in adults and for the treatment of cluster headaches. Emgality has been well-received due to its clinical efficacy and convenient administration via a pre-filled syringe or autoinjector pen[3].

Market Reception and Sales

Since its approval in September 2018, Emgality has shown impressive sales figures. In 2021, Emgality generated $435 million in the US and $577 million globally. Analysts forecast peak sales of $1.27 billion by 2025, indicating strong market reception and growth potential[3].

Competitive Landscape

Emgality competes in a crowded market with other CGRP inhibitors such as Amgen’s Aimovig and Teva’s Ajovy. Despite this competition, Emgality has managed to carve out a significant market share due to its clinical results, convenient administration, and favorable reimbursement scenarios. The drug received coverage from major pharmacy benefit managers (PBMs) like Express Scripts, OptumRx, and CVS, further boosting its market presence[3][4].

Pricing and Cost Considerations

The cost of Emgality is a significant factor for patients. Without insurance, the retail price of Emgality averages around $879 for a single 120 mg autoinjector, which translates to nearly $10,000 per year for continuous treatment. However, many commercial health insurance policies cover Emgality, and patients can also benefit from manufacturer assistance programs, discount cards like SingleCare, and other savings options to reduce the out-of-pocket expenses[5].

Regional Insights

North America, particularly the United States, dominates the migraine drugs market, with a high prevalence of migraines affecting approximately 12% of the population. The Asia-Pacific region is also expected to see significant growth due to increased demand for better healthcare services and strengthened healthcare infrastructure[1][4].

Factors Driving Market Growth

Several factors are driving the growth of the migraine drugs market, including:

• Advancements in Novel Therapies: The introduction of CGRP inhibitors like Emgality has revolutionized migraine treatment, offering patients more effective and personalized treatment options[1].
• Increasing Prevalence: The high prevalence of migraines globally, affecting around 12% of the population, presents a significant market opportunity[1].
• Favorable Reimbursement Scenarios: Positive reimbursement policies for migraine medications, especially for CGRP inhibitors, have facilitated patient access and driven sales[4].
• Awareness and Research: Increased awareness initiatives and availability of research funds have contributed to the growth of the market[4].

Price Projections and Cost Management

Given the current market trends and the competitive landscape, here are some key points regarding price projections and cost management for Emgality:

• Price Stability: Despite some concerns about potential price increases, there is no confirmed plan to change the pricing for Emgality in 2024, at least in regions where CDC Pharmaceuticals is the supplier[2].
• Discounts and Savings: Patients can utilize discount cards, manufacturer assistance programs, and compare pharmacy prices to reduce the cost of Emgality. For example, using a SingleCare discount card can lower the price from around $879 to less than $530[5].
• Insurance Coverage: Many insurance plans, including some Medicare Part D and Medicaid plans, cover Emgality, which helps in managing the cost for patients[5].

Future Outlook

The future outlook for Emgality and the broader migraine drugs market is promising. Here are some key points:

• Market Growth: The migraine drugs market is expected to continue growing, driven by the increasing prevalence of migraines and advancements in treatment options[1].
• Competitive Dynamics: The market will remain competitive with multiple CGRP inhibitors available, but Emgality’s strong clinical results and convenient administration are likely to maintain its market share[3][4].
• Cost Management: Efforts to manage costs through discounts, insurance coverage, and manufacturer programs will continue to be crucial for patient access and market growth[5].

Key Takeaways

• Market Size and Growth: The migraine drugs market is projected to reach US$ 6.3 billion by 2032, with a CAGR of 4.3% during the forecast period.
• Emgality’s Role: Emgality is a significant player in the market, known for its clinical efficacy and convenient administration.
• Pricing and Cost: The cost of Emgality is high without insurance, but various savings options and insurance coverage help manage the expenses.
• Future Outlook: The market is expected to grow, driven by increasing prevalence and advancements in treatments.

FAQs

1. What is Emgality used for? Emgality is used for the preventive treatment of migraine in adults and for the treatment of cluster headaches.

2. How much does Emgality cost without insurance? Without insurance, the retail price of Emgality averages around $879 for a single 120 mg autoinjector.

3. Is Emgality covered by insurance? Yes, many commercial health insurance policies and some Medicare Part D and Medicaid plans cover Emgality.

4. How can patients reduce the cost of Emgality? Patients can use discount cards like SingleCare, manufacturer assistance programs, and compare pharmacy prices to reduce the cost.

5. What are the key factors driving the growth of the migraine drugs market? The key factors include advancements in novel therapies, increasing prevalence of migraines, favorable reimbursement scenarios, and increased awareness initiatives.

Sources

1. Biospace: Migraine Drugs Market Size to Reach USD 6.3 Billion by 2032...
2. Migraine Foundation: Emgality price increase? Thankfully not...
3. Phil Inc: Migraine - Post Approval Insights...
4. GlobeNewswire: Migraine Drugs Market To Reach USD 3.51 Billion By 2026...
5. SingleCare: How much is Emgality without insurance?...